Enter the vial size and the bacteriostatic water you added to get the concentration and the micrograms carried by each unit on a U-100 syringe. HGH Fragment 176-191 has no human trial of its own and no stated dose, so this page does the arithmetic, not the recommendation. The compound itself is covered in the HGH Fragment 176-191 guide.
A 5 mg vial of HGH Fragment 176-191 reconstituted with 2 mL of bacteriostatic water gives a concentration of 2.5 mg/mL, or 25 mcg per unit on a U-100 syringe.
Defaults: 5 mg is the most common labelled vial among the HGH Fragment 176-191 tests on file, 21 Sep 2026 (36 of 62); 2 mL was chosen for simple arithmetic and is not a sourced volume. Peptigrity publishes no HGH Fragment 176-191 dose, so the dose field starts empty.
Draw the syringe up to
Enter your own amount to see the draw. Add 2 mL of water to your 5 mg vial first.
HGH Fragment 176-191 has 62 independent lab tests on file at Peptigrity, averaging 99.01% HPLC purity across the tests that report one. Purity is not net content: a clean certificate confirms what is in a vial, not how much. See the HGH Fragment 176-191 lab-test records.
HGH Fragment 176-191 is a synthetic 16-amino-acid C-terminal fragment of human growth hormone (residues 176 through 191), researched for lipolysis without the proliferative or insulin-resistance effects of full-length GH. The evidence for this molecule is preclinical: no human clinical trial of the unmodified fragment has been published. The human record that circulates under its name belongs to AOD-9604, a separately catalogued analog, which ran six placebo-controlled trials (about 893 participants) and was discontinued in 2007 after its 24-week Phase 2b obesity trial missed its primary weight-loss endpoint. With no trial of its own, the fragment has no studied quantity to cite, and the compound page declines to state one.
The table summarises what the HGH Fragment 176-191 compound page states (last updated August 2026).
| Question | What the compound page states | Evidence level |
|---|---|---|
| What is it? | A synthetic 16-amino-acid C-terminal fragment of human growth hormone (CAS 66004-57-7) | Chemical identity |
| Is it AOD-9604? | No — AOD-9604 (CAS 221231-10-3) is its analog with an added N-terminal tyrosine, catalogued separately | Chemical identity |
| Human studies? | None published for the unmodified fragment; the human data belongs to AOD-9604 | Preclinical (rodent lipolysis) |
| An approved dose? | Not approved for any medical indication anywhere in the world (as of August 2026) | None |
| A research dose? | None stated; no route stated either | None — declined |
One practical consequence: the compound page warns that HGH Fragment 176-191 and AOD-9604 are not reliably distinguished by standard HPLC purity testing, that some vendors label one as the other, and that molecular-weight figures for the pair are reported inconsistently across sources — sequence and CAS number, not a quoted mass, tell them apart. The arithmetic below converts the milligrams on a label into units; it cannot tell you which of the two molecules is in the vial. Only mass-spectrometry identity confirmation on a certificate can. If your vial is labelled AOD-9604, the AOD-9604 calculator does the same arithmetic alongside the evidence for that molecule.
The table converts reference quantities to syringe units at the default of 2.5 mg/mL (5 mg of HGH Fragment 176-191 in 2 mL), and counts how many draws of each a vial holds. Every row is arithmetic, not a dose: read the units for the amount you already intend to measure.
| Quantity | Draw at 2.5 mg/mL | Volume | Draws from a 2 mg vial | Draws from a 5 mg vial |
|---|---|---|---|---|
| 50 mcg | 2.0 units | 0.02 mL | 40 | 100 |
| 100 mcg | 4.0 units | 0.04 mL | 20 | 50 |
| 250 mcg | 10.0 units | 0.10 mL | 8 | 20 |
| 500 mcg | 20.0 units | 0.20 mL | 4 | 10 |
| 1 mg | 40.0 units | 0.40 mL | 2 | 5 |
The same HGH Fragment 176-191 quantity lands on a different mark depending on how much water went into the vial. Read down the column for the concentration you actually mixed; a units figure carried across from another column is simply wrong.
| Quantity | At 5.0 mg/mL (5 mg + 1 mL) | At 2.5 mg/mL (5 mg + 2 mL) | At 1.0 mg/mL (5 mg + 5 mL) |
|---|---|---|---|
| 50 mcg | 1.0 units | 2.0 units | 5.0 units |
| 100 mcg | 2.0 units | 4.0 units | 10.0 units |
| 250 mcg | 5.0 units | 10.0 units | 25.0 units |
| 500 mcg | 10.0 units | 20.0 units | 50.0 units |
| 1 mg | 20.0 units | 40.0 units | 100.0 units |
Every cell is the same arithmetic: units = (quantity in mg ÷ concentration in mg/mL) × 100 on a U-100 syringe. More water spreads the same mass over more units, which is the fix when a small quantity would otherwise sit at two or three units, where a one-unit misread is a large error.
Each HGH Fragment 176-191 vial holds as many draws as its labelled mass divided by the quantity per draw; the water volume changes nothing about it. The grid counts draws, not weeks — this page states no frequency.
| Vial size | At 50 mcg | At 100 mcg | At 250 mcg | At 500 mcg | At 1 mg |
|---|---|---|---|---|---|
| 2 mg | 40 | 20 | 8 | 4 | 2 |
| 5 mg | 100 | 50 | 20 | 10 | 5 |
| 10 mg | 200 | 100 | 40 | 20 | 10 |
The labelled mass is not a guarantee of the mass in your vial: net content is a separate measurement from purity, and certificates on file often measure a few percent above or below the label.
No label sets a diluent volume for research-grade HGH Fragment 176-191, and the compound page states none, so the volume is a choice. The one decision with real consequences is resolution: a small quantity drawn from a strong solution sits at two or three units, where a one-unit misread is a large error, and the fix is more water. The technique is covered once, elsewhere: reconstituting peptides step by step and the bacteriostatic water guide. Storage and in-use guidance there is general peptide guidance, not an HGH Fragment 176-191-specific finding.
HGH Fragment 176-191 is not approved for any medical indication anywhere in the world as of August 2026, and is sold as a research-use-only material. Neither the native fragment nor AOD-9604 is on the FDA's 503A list of bulk drug substances eligible for compounding, and the FDA's Pharmacy Compounding Advisory Committee voted against including AOD-9604 at its December 4, 2024 meeting. For tested athletes, growth-hormone fragments — including HGH Fragment 176-191 and AOD-9604 — are prohibited at all times by the World Anti-Doping Agency under Section S2.2.3 of the Prohibited List.
Independent test records: HGH Fragment 176-191 lab tests. Tracked prices: HGH Fragment 176-191 price per milligram. The analog that reached human trials has its own pages: the AOD-9604 guide and the AOD-9604 calculator.
It depends on the concentration. At the page default of 2.5 mg/mL (a 5 mg vial with 2 mL of water), each unit on a U-100 syringe carries 25 mcg, so 250 mcg is 10 units (0.10 mL). With 1 mL in the same vial (5 mg/mL) it is 5 units; with 5 mL (1 mg/mL) it is 25 units. A units figure quoted without a concentration cannot be used.
There isn't one. No human clinical trial of the unmodified fragment has been published, the compound is not approved for any medical indication, and Peptigrity does not recommend a dose. Human data attributed to the fragment in circulation mostly comes from AOD-9604, a different molecule. This calculator converts a quantity you already have in mind into syringe units; it does not supply the quantity.
No. HGH Fragment 176-191 (CAS 66004-57-7) is the native, unmodified C-terminal fragment of growth hormone. AOD-9604 (CAS 221231-10-3) is its analog with an added N-terminal tyrosine, and it is the version that reached human trials. The two are not reliably distinguished by HPLC purity testing alone; mass-spectrometry identity confirmation is needed.
No. The calculator works on the labelled mass in milligrams. The compound page notes that molecular-weight figures for HGH Fragment 176-191 and AOD-9604 are reported inconsistently across sources, so sequence and CAS number, not a quoted mass, are the reliable way to tell them apart.
Yes. Growth-hormone fragments, including HGH Fragment 176-191 and AOD-9604, are prohibited at all times by the World Anti-Doping Agency under Section S2.2.3 of the Prohibited List.